Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia.

Literature DB >> 8997563

Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia.

J L Muñoz¹, M I García, S Muñoz, S Leal, M Fajardo, J A Garćia-Rodríguez.

Abstract

The inhibitory activity of eight antibiotics and the inhibitory and bactericidal activities of combinations of trimethoprim/sulfamethoxazole (TMP/SMX) plus three fixed concentrations of polymyxin B (0.01 microgram/ml, 0.1 microgram/ml and 0.5 microgram/ml) against 30 multi-resistant strains of Stenotrophomonas maltophilia were tested. Polymyxin B at 0.01 microgram/ml modified the inhibitory activity of TMP/SMX against only 40% of strains. At 0.1 microgram/ml and 0.5 microgram/ml, polymyxin B enhanced the inhibitory activity of TMP/SMX activity against all strains. Polymyxin B enhanced the bactericidal activity of TMP/SMX only at concentrations near the minimum inhibitory concentration of polymyxin B alone.

Entities: Chemical Species

Mesh：

Substances：

Year: 1996 PMID： 8997563 DOI： 10.1007/bf01691222

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

13 in total

1. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer.

Authors: N Khardori; L Elting; E Wong; B Schable; G P Bodey
Journal: Rev Infect Dis Date: 1990 Nov-Dec

2. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors.

Authors: L S Elting; N Khardori; G P Bodey; V Fainstein
Journal: Infect Control Hosp Epidemiol Date: 1990-03 Impact factor: 3.254

3. Resistance of Xanthomonas maltophilia to antibiotics and the effect of beta-lactamase inhibitors.

Authors: H C Neu; G Saha; N X Chin
Journal: Diagn Microbiol Infect Dis Date: 1989 May-Jun Impact factor: 2.803

4. Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors: A W Chow; J Wong; K H Bartlett
Journal: Antimicrob Agents Chemother Date: 1988-05 Impact factor: 5.191

5. A changing pattern of susceptibility of Xanthomonas maltophilia to antimicrobial agents: implications for therapy.

Authors: S Vartivarian; E Anaissie; G Bodey; H Sprigg; K Rolston
Journal: Antimicrob Agents Chemother Date: 1994-03 Impact factor: 5.191

6. Combined activity of sulfamethoxazole, trimethoprim, and polymyxin B against gram-negative bacilli.

Authors: J E Rosenblatt; P R Stewart
Journal: Antimicrob Agents Chemother Date: 1974-07 Impact factor: 5.191

7. Susceptibility of Pseudomonas maltophilia to antimicrobial agents, singly and in combination.

Authors: T P Felegie; V L Yu; L W Rumans; R B Yee
Journal: Antimicrob Agents Chemother Date: 1979-12 Impact factor: 5.191

8. Synergistic interaction in vitro with use of three antibiotics simultaneously against Pseudomonas maltophilia.

Authors: V L Yu; T P Felegie; R B Yee; A W Pasculle; F H Taylor
Journal: J Infect Dis Date: 1980-10 Impact factor: 5.226

9. Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of beta-lactam/beta-lactamase inhibitor combinations.

Authors: J A García-Rodríguez; J E García Sánchez; M I García García; E García Sánchez; J L Muñoz Bellido
Journal: Diagn Microbiol Infect Dis Date: 1991 May-Jun Impact factor: 2.803

3. Monotherapy with fluoroquinolone or trimethoprim-sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections.

Authors: Yu Lin Wang; Marco R Scipione; Yanina Dubrovskaya; John Papadopoulos
Journal: Antimicrob Agents Chemother Date: 2013-10-21 Impact factor: 5.191

3 in total